Pfizer (UKEX:PFE) Cyclically Adjusted Revenue per Share: ₴440.19 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:PFE Pfizer Inc UKEX:PFE
73 GF Score
Price ₴1,014.00
GF Value ₴1,049.09
! 5 Warning Signs
View Full Analysis

What is Pfizer Cyclically Adjusted Revenue per Share?

Pfizer UKEX:PFE 73 Cyclically Adjusted Revenue per Share is ₴440.19 as of Mar. 2026. GuruFocus rates UKEX:PFE with a GF Score™ of 73/100 and a GF Value™ of ₴1,049.09. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pfizer's adjusted revenue per share for the three months ended in Mar. 2026 was ₴112.590. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₴440.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pfizer's average Cyclically Adjusted Revenue Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pfizer was 13.90% per year. The lowest was -0.10% per year. And the median was 5.20% per year.

As of today (2026-07-17), Pfizer's current stock price is ₴1014.00. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₴440.19. Pfizer's Cyclically Adjusted PS Ratio of today is 2.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 4.02.


Pfizer  (UKEX:PFE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1014.00/440.19
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 4.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pfizer Cyclically Adjusted Revenue per Share Related Terms


Pfizer Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted Revenue per Share Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 426.72 445.66 488.67

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 472.99 498.63 478.74 488.67 440.19

UKEX:PFE vs GILD, BMY, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


UKEX:PFE
73GF Score
Pfizer Inc UKEX:PFE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=112.59/330.2130*330.2130
=112.590

Current CPI (Mar. 2026) = 330.2130.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 95.474 241.018 130.807
201609 94.718 241.428 129.550
201612 99.582 241.432 136.201
201703 93.670 243.801 126.870
201706 95.389 244.955 128.590
201709 97.336 246.819 130.223
201712 100.956 246.524 135.228
201803 95.147 249.554 125.900
201806 101.027 251.989 132.388
201809 99.200 252.439 129.763
201812 8.721 251.233 11.463
201903 101.874 254.202 132.336
201906 104.424 256.143 134.621
201909 100.233 256.759 128.908
201912 14.618 256.974 18.784
202003 80.215 258.115 102.621
202006 78.389 257.797 100.409
202009 81.468 260.280 103.357
202012 90.121 260.474 114.250
202103 114.483 264.877 142.722
202106 148.630 271.696 180.641
202109 187.470 274.310 225.675
202112 184.547 278.802 218.577
202203 199.005 287.504 228.567
202206 216.876 296.311 241.690
202209 176.790 296.808 196.687
202212 195.367 296.797 217.363
202303 144.130 301.836 157.680
202306 101.658 305.109 110.022
202309 106.708 307.789 114.482
202312 114.263 306.746 123.004
202403 116.617 312.332 123.293
202406 104.133 314.175 109.449
202409 138.550 315.301 145.103
202412 139.091 315.605 145.529
202503 107.256 319.799 110.749
202506 114.672 322.561 117.392
202509 130.149 324.800 132.318
202512 137.014 324.054 139.618
202603 112.590 330.213 112.590

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₴440.19 mean?
Pfizer (UKEX:PFE) has a Cyclically Adjusted Revenue per Share of ₴440.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors.
Is Pfizer's Cyclically Adjusted Revenue per Share too high?
Pfizer's current Cyclically Adjusted Revenue per Share is ₴440.19. Overall, Pfizer has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cyclically Adjusted Revenue per Share compare to GILD and BMY?
Pfizer's Cyclically Adjusted Revenue per Share of ₴440.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors. Pfizer's current Cyclically Adjusted Revenue per Share is ₴440.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Pfizer (UKEX:PFE) has a current Cyclically Adjusted Revenue per Share of ₴440.19. The stock's GF Value™ is ₴1,049.09, compared to a current price of ₴1,014.00 — trading 3.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₴440.19. Pfizer's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pfizer (UKEX:PFE), the current Cyclically Adjusted Revenue per Share is ₴440.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (UKEX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ₴1,014.00 is trading 3.3% below its estimated GF Value™ of ₴1,049.09.

Key valuation signals for UKEX:PFE:

  • Cyclically Adjusted Revenue per Share: ₴440.19
  • GF Value™: ₴1,049.09 vs. price of ₴1,014.00 (3.3% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the UKEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
73GF Score

Get the complete analysis for UKEX:PFE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴1,014.00
Price
₴1,049.09
GF Value